Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2858 in advanced cervical cancer
NCT05068921Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Dec 2021
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bemosesuglimab in Cervical Cancer (CC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Objective Response Rate up to 2 years. Status: unknown.
02
Drugs
bemosesuglimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05068921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05068921.